Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Rhea-AI Summary

Biofrontera (Nasdaq: BFRI) announced the FDA has accepted its supplemental New Drug Application for Ameluz® PDT to treat superficial basal cell carcinoma (sBCC) and assigned a PDUFA target action date of September 28, 2026. The FDA identified no filing deficiencies. If approved, Ameluz® would expand beyond its current FDA approval for actinic keratosis and could become the first PDT photosensitizer indicated for sBCC, a subtype representing roughly 10–25% of the ~3.6 million annual U.S. basal cell carcinoma cases. The company says this could broaden Ameluz®’s clinical use and address unmet non‑surgical needs in dermatology.

Positive

• FDA accepted sNDA with no filing deficiencies and set PDUFA for Sept 28, 2026
• First-ever potential PDT photosensitizer indication for sBCC if approved
• Expands Ameluz® clinical use beyond actinic keratosis, potentially increasing addressable market

Negative

• Regulatory outcome uncertain until the Sept 28, 2026 PDUFA decision
• sBCC comprises an estimated 10–25% of BCC cases, limiting the subset of total BCC market

News Market Reaction – BFRI

-1.29%

7 alerts

-1.29% News Effect

+31.1% Peak Tracked

-2.6% Trough Tracked

-$119K Valuation Impact

$9M Market Cap

0.0x Rel. Volume

On the day this news was published, BFRI declined 1.29%, reflecting a mild negative market reaction. Argus tracked a peak move of +31.1% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $119K from the company's valuation, bringing the market cap to $9M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PDUFA target date: September 28, 2026 BCC annual cases: 3.6 million sBCC share of BCC: 10–25% +5 more

8 metrics

PDUFA target date September 28, 2026 FDA action date for Ameluz sNDA in superficial BCC

BCC annual cases 3.6 million Estimated yearly basal cell carcinoma cases in the US

sBCC share of BCC 10–25% Published estimates of BCC cases that are superficial subtype

sBCC Phase 3 patients 187 patients Randomized U.S. Phase 3 sBCC study in prior sNDA filing

sBCC primary clearance 65.5% vs 4.8% Ameluz-PDT vs placebo complete clearance in sBCC Phase 3

Pre-news price change -3.74% Move over prior 24h before FDA filing acceptance news

52-week range $0.536–$1.19 Pre-news 52-week low and high for BFRI

Market cap $9,438,636 Pre-news market capitalization

Market Reality Check

Price: $0.8628 Vol: Volume 285,745 is well be...

low vol

$0.8628 Last Close

Volume Volume 285,745 is well below 20-day average 836,753 (relative volume 0.34) ahead of this news. low

Technical Shares at $0.78 were trading below the 200-day MA of $0.84 and 34.45% under the 52-week high.

Peers on Argus

Pre-news, BFRI was down 3.74% while momentum peers like CPHI and INM were both m...

2 Down

Pre-news, BFRI was down 3.74% while momentum peers like CPHI and INM were both moving down without news. Scanner data flags 2 peers moving, but not in the same direction, suggesting a stock-specific setup rather than a coordinated sector move.

Previous Clinical trial Reports

5 past events · Latest: Feb 09 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Phase 3 results	Positive	-1.3%	Positive Phase 3 AK data on extremities, neck, and trunk meeting primary endpoint.
Jan 08	Data lock update	Positive	+3.1%	Database locks for Phase 3 AK and Phase 2 acne studies enabling topline data.
Dec 04	Phase 1 completion	Positive	+3.2%	Last patient completed Phase 1 PK study for Ameluz on trunk and extremities.
Dec 02	sNDA submission	Positive	-0.1%	sNDA filed for Ameluz-PDT to treat superficial basal cell carcinoma in the US.
Sep 16	Phase 3 milestone	Positive	+4.0%	Last patient out in Phase 3 AK study on extremities, neck, and trunk.

Pattern Detected

Clinical and regulatory trial updates have usually been received positively, but reactions are mixed, with several positive trial milestones followed by modest or negative next-day moves.

Recent Company History

Over the past six months, Biofrontera has steadily advanced its Ameluz® PDT franchise across multiple indications. Key milestones include Phase 3 success for actinic keratoses on extremities, neck, and trunk on Feb 9, 2026, database locks for pivotal AK and acne studies on Jan 5, 2026, and a Phase 1 pharmacokinetics completion on Nov 24, 2025. Earlier, the company filed an sNDA for superficial basal cell carcinoma on Nov 28, 2025 and reported last patient out in a major Phase 3 AK trial in Q3 2025. Today’s FDA filing acceptance fits this ongoing clinical and regulatory expansion of Ameluz®.

Historical Comparison

+1.8% avg move · Across 5 recent clinical-trial updates, average next-day move was +1.78%, with mostly positive senti...

clinical trial

+1.8%

Average Historical Move clinical trial

Across 5 recent clinical-trial updates, average next-day move was +1.78%, with mostly positive sentiment but mixed price follow-through.

Clinical news has progressed from last-patient-out and PK completion through sNDA submission for sBCC, culminating in FDA acceptance of the sNDA and a defined PDUFA action date.

Market Pulse Summary

This announcement marks FDA acceptance of Biofrontera’s sNDA for Ameluz® PDT in superficial basal ce...

Analysis

This announcement marks FDA acceptance of Biofrontera’s sNDA for Ameluz® PDT in superficial basal cell carcinoma, with a PDUFA action date of September 28, 2026. It extends a sequence of positive clinical milestones and prior sNDA activity around Ameluz®. At the same time, recent filings highlight going‑concern risk and Nasdaq listing pressures. Investors may focus on future trial readouts, regulatory interactions, and execution toward commercialization in sBCC and expanded AK labeling.

Key Terms

prescription drug user fee act, pdufa, supplemental new drug application, snda, +4 more

8 terms

prescription drug user fee act regulatory

"Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026"

A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.

pdufa regulatory

"Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026"

PDUFA, short for the Prescription Drug User Fee Act, is a law that allows drug companies to pay fees to the government to speed up the review process for new medicines. This helps bring important drugs to market more quickly, which can impact their availability and pricing. For investors, PDUFA timelines can influence the timing of a drug’s approval and potential market success.

supplemental new drug application regulatory

"accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz"

A supplemental new drug application is a request submitted to regulatory authorities to make changes to an existing approved medication, such as adding new uses, strengths, or formulations. For investors, it signals that a pharmaceutical company is seeking approval for new product developments or expanded applications, which can impact the company's future sales, market potential, and stock value.

snda regulatory

"accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz"

A SNDA (Subordination, Non‑Disturbance and Attornment Agreement) is a legal pact among a property owner’s lender, the owner’s tenants, and sometimes the landlord that sets who keeps lease rights if the property is sold or a mortgage is enforced. Think of it as a rulebook that decides whether a tenant can stay and keep paying rent or must answer to a new owner after a foreclosure. For investors, an SNDA matters because it protects predictable rental income, clarifies who has priority on claims against a property, and therefore affects a property’s value and the security of related loans.

photodynamic therapy medical

"a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT)"

Photodynamic therapy is a medical treatment that uses a special light-sensitive substance and a specific type of light to target and destroy abnormal or diseased cells, often in cancer treatment. It is important to investors because advances in this technology can lead to new, minimally invasive treatment options, potentially expanding healthcare markets and driving growth for biotech companies involved in developing such therapies.

pdt medical

"photodynamic therapy (PDT), today announced that the U.S. Food and Drug Administration"

PDT stands for “pattern day trader,” a regulatory designation applied to brokerage accounts that make frequent same-day buy-and-sell trades within a short period. It matters because once an account is labeled, the broker requires a minimum equity balance and imposes limits on how often the account can trade, which is like needing a higher license to drive faster — it changes how easily and quickly an investor can execute active trading strategies.

photosensitizer medical

"Ameluz would be the first and only PDT photosensitizer indicated for the treatment"

A photosensitizer is a drug or chemical that becomes active when exposed to a specific light wavelength, enabling it to kill targeted cells or produce a detectable signal. Investors care because these compounds are central to light‑activated treatments and diagnostic tools—think of them as a light switch that turns a medicine on only where needed—so their effectiveness, safety, manufacturing, regulatory approval, and patent protection directly affect a product’s commercial potential.

topical gel medical

"Ameluz (aminolevulinic acid hydrochloride) topical gel used in combination with the RhodoLED"

A topical gel is a medicine or active formula delivered as a semi-solid, smooth substance applied directly to the skin or mucous membranes to treat local symptoms or deliver drugs through the skin. For investors, it matters because this delivery form affects manufacturing complexity, regulatory review, shelf life, and market appeal—think of it like choosing a spray versus a pill: the format influences cost, patient acceptance, and potential sales.

AI-generated analysis. Not financial advice.

• Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026
• If approved, Ameluz^® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the US
• BCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually¹
  
  

WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz^® (aminolevulinic acid hydrochloride) topical gel used in combination with the RhodoLED^® red-light lamp series for the treatment of sBCC. The FDA identified no filing deficiencies and assigned a PDUFA target action date of September 28, 2026.

If approved, this new indication would represent a significant clinical expansion of the Ameluz^® PDT platform beyond its existing FDA approval for treatment of actinic keratosis. It would also further validate Biofrontera’s PDT approach, which combines Ameluz^®’s nanoemulsion technology with red-light illumination designed to penetrate deeper into tissue compared with shorter wavelengths of light such as green and blue, enabling treatment of lesions extending into deeper skin layers.

Basal cell carcinoma is the most common cancer in the U.S., with approximately 3.6 million cases diagnosed annually¹, and published estimates suggest that 10–25% of these cases are of the superficial subtype^2,3,4. Current treatment options often rely on surgical or destructive approaches, which may not be appropriate or preferred for all patients.

“We are proud of the investments we continue to make in this specialty. This milestone represents an important step forward in our strategy to expand the clinical utility of Ameluz^® and reinforce photodynamic therapy as a versatile platform in dermatology,” said Dr. Hermann Luebbert, Chief Executive Officer of Biofrontera. “The FDA’s acknowledgement of no filing deficiencies in our sNDA reflects the strength of the data package and allows us to move forward with confidence toward a potential new indication that addresses a meaningful unmet medical need.”

If approved, Ameluz^® PDT for the treatment of sBCC would offer dermatology providers and their patients a non-invasive treatment option aligned with real-world practice needs. Biofrontera believes this indication has the potential to meaningfully expand the addressable market for Ameluz^® and strengthen the Company’s position in medical dermatology.

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz^® with the RhodoLED^® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers⁵. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

References

1. https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/
2. Cameron MC et al, J. Am. Acad. Dermatol. 2019;80(2):303-317
3. Cameron MC et al., J. Am. Acad. Dermatol. 2019;80(2):321–339
4. Marzuka AG and Book SE. Yale J Biol Med. 2015;88(2):167-179
   
   

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz^® in combination with BF-RhodoLED^® and/or RhodoLED^® XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; the Company’s ability to achieve and sustain profitability; whether global disruptions in supply chains will impact the Company’s ability to obtain and distribute its products; changes in the practices of healthcare providers, including any changes to coverage, reimbursement and pricing for procedures using the Company’s products; whether the market opportunity for Ameluz^® in combination with BF- RhodoLED^® and/or RhodoLED^® XL is consistent with the Company’s expectations; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

FAQ

What did Biofrontera (BFRI) announce about Ameluz® on February 11, 2026?

The company announced FDA acceptance of an sNDA for Ameluz® PDT to treat sBCC with no filing deficiencies. According to the company, the FDA assigned a PDUFA target action date of September 28, 2026 and allowed the review to proceed.

What does the PDUFA date of September 28, 2026 mean for BFRI shareholders?

It marks the FDA review deadline for the sNDA and a potential catalyst for the stock. According to the company, a decision by Sept 28, 2026 will determine approval status and next commercial steps.

How would FDA approval of Ameluz® for sBCC affect its clinical positioning?

Approval would expand Ameluz® from actinic keratosis into sBCC, creating a broader PDT platform in dermatology. According to the company, this would offer a non‑invasive alternative to surgical or destructive treatments for eligible patients.

What is the size of the patient population targeted by Ameluz® for sBCC?

Basal cell carcinoma affects about 3.6 million U.S. cases yearly, with 10–25% estimated as superficial subtype. According to the company, this defines the potential addressable sBCC subset for Ameluz® therapy.

Did the FDA find any deficiencies in Biofrontera’s sNDA filing for Ameluz®?

No, the FDA identified no filing deficiencies and accepted the sNDA for review. According to the company, this acceptance enabled assignment of the September 28, 2026 PDUFA target action date.